NovaBay Pharmaceuticals Q2 2023 Earnings Report

NovaBay Pharmaceuticals EPS Results

• Actual EPS: -$1.27
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

NovaBay Pharmaceuticals Revenue Results

• Actual Revenue: $4.61 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

NovaBay Pharmaceuticals Announcement Details

• Quarter: Q2 2023
• Date: 8/10/2023
• Time: N/A
• Conference Call Date: Thursday, August 10, 2023
• Conference Call Time: 4:30PM ET

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) is a clinical‐stage biopharmaceutical company dedicated to developing and commercializing novel anti‐infective products based on its proprietary Aganocide® technology platform. The company’s primary focus lies in addressing serious eye care conditions, wound care and disinfectant applications through small-molecule agents designed to mimic the body’s natural defense mechanisms against microbial pathogens.

Among its leading products, Avenova® is an FDA-cleared eyelid and lash hygiene treatment indicated for the management of chronic dry eye and blepharitis, offering a preservative‐free, sterile solution for daily eyelid hygiene. NeutroPhase® is an advanced wound irrigation and topical therapy designed to aid in the treatment of acute and chronic wounds, leveraging the antimicrobial properties of its active ingredient to promote faster healing. Additionally, ClearAqua™ serves as a broad‐spectrum disinfectant for medical devices and hard surfaces, meeting rigorous regulatory standards for environmental decontamination.

Founded in 2000 and headquartered in Emeryville, California, NovaBay has expanded its commercial reach across North America, Europe and selected Asian markets through strategic partnerships and distribution agreements. The company has established collaborative relationships with academic institutions and contract manufacturers to support its ongoing clinical programs and supply chain operations, while pursuing regulatory approvals in key markets worldwide.

Guided by an experienced leadership team led by Chief Executive Officer Jiande Wu, NovaBay continues to advance its pipeline through rigorous clinical validation and regulatory engagement. The company remains focused on leveraging its Aganocide® platform to address unmet medical needs, enhancing patient outcomes and driving long-term value in the anti‐infective therapeutics sector.

NovaBay Pharmaceuticals Q2 2023 Earnings Call Transcript

Key Takeaways

• The transcript only contains closing remarks and does not include any financial results or commentary.
• No performance metrics or operational updates were discussed during the call.
• There were no forward-looking statements or guidance provided to investors.

[Operator]

Have a nice day. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.